In the months since the novel coronavirus rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic.

Some are repurposing old antivirals. Some are mobilizing tried-and-true technologies, and others are pressing forward with futuristic approaches to human medicine.

Here’s a guide to some of the most talked-about efforts to treat or prevent coronavirus infection, with details on the science, history, and timeline for each endeavor.

advertisement

Gilead Sciences

Approach: Treatment
Stage: Phase 3

Gilead’s remdesivir, an intravenous treatment, has already been used to treat one infected patient in the U.S. and will soon be deployed in a pair of large, late-stage studies in Asia. Later this month, Gilead will recruit about 1,000 patients diagnosed with the coronavirus to determine whether multiple doses of remdesivir can reverse the infection. The primary goals are reducing fever and helping patients get out of the hospital within two weeks. The drug, which previously failed in a study on Ebola virus, is also being studied in smaller trials in China and the U.S.

advertisement

Support STAT: If you value our coronavirus coverage, please consider making a one-time contribution to support our journalism. You can help us continue to produce authoritative pieces from the frontiers of health and medicine.

Moderna Therapeutics

Approach: Vaccine
Stage: Phase 1

Moderna set a drug industry record with mRNA-1273, a vaccine candidate identified just 42 days after the novel coronavirus was sequenced. The company is working with the National Institutes of Health on a healthy-volunteer study expected to begin next month. If mRNA-1273 proves itself to be safe, the two organizations will enroll hundreds more patients to determine whether the vaccine protects against infection. Moderna’s product is a synthetic strand of messenger RNA, or mRNA, designed to convince bodily cells to produce antibodies against the virus. The company, founded in 2010, is yet to win Food and Drug Administration approval for any of its mRNA medicines.

CureVac

Approach: Vaccine
Stage: Preclinical

Like Moderna, CureVac uses man-made mRNA to spur the production of proteins. And, like Moderna, it got a grant from the nonprofit Coalition for Epidemic Preparedness Innovations to apply its technology to coronavirus. CureVac has said it expects to have a candidate ready for human testing within a few months. The company is also working with CEPI on a mobile mRNA manufacturing technology, one that would theoretically allow health care workers to rapidly produce vaccines to respond at the site of an outbreak.

GlaxoSmithKline

Approach: Vaccine
Stage: Preclinical

GlaxoSmithKline, one of the world’s largest vaccine manufacturers, is lending its technology to a Chinese biotech firm at work on a coronavirus vaccine. Under an agreement signed last month, GSK is providing its proprietary adjuvants — compounds that enhance the effectiveness of vaccines — to Clover Biopharmaceuticals, a privately held company based in Chengdu. Clover’s approach involves injecting proteins that spur an immune response, thereby priming the body to resist infection. The company has not said when it expects to advance into human testing.

Inovio Pharmaceuticals

Approach: Vaccine
Stage: Preclinical

Inovio has spent the last four decades working to turn DNA into medicine, and the company believes its technology could quickly generate a vaccine for the novel coronavirus. Working with CEPI grant money, Inovio has come up with a DNA vaccine it believes can generate protective antibodies and keep patients from infection. The company has partnered with a Chinese manufacturer, Beijing Advaccine Biotechnology, and is working through preclinical development with a candidate called INO-4800. The company expects to progress into clinical trials later this year.

Support STAT: If you value our coronavirus coverage, please consider making a one-time contribution to support our journalism. You can help us continue to produce authoritative pieces from the frontiers of health and medicine.

 

Johnson & Johnson

Approach: Vaccine and treatment
Stage: Preclinical

Johnson & Johnson, which has in the past responded to outbreaks of the Ebola and Zika viruses, is taking a multipronged approach to the coronavirus. The company is in the early days of developing a vaccine that would introduce patients to a deactivated version of the virus, triggering an immune response without causing infection. At the same time, J&J is working with the federal Biomedical Advanced Research and Development Authority on potential treatments for patients who are already infected, a process that includes investigating whether any of its older medicines might work against the coronavirus.

Regeneron Pharmaceuticals

Approach: Treatment
Stage: Preclinical

Regeneron has grown into a $50 billion business based on its ability to craft human antibodies out of genetically engineered mice. Now it’s tapping that technology in hopes of treating coronavirus. The company is immunizing its antibody-generating mice with a harmless analog of the novel coronavirus, generating potential treatments for the infection. The most potent antibody results will go into animal testing, and if everything goes according to plan, Regeneron will be ready for human testing by late summer. The last time Regeneron embarked on this process, during the Ebola outbreak of 2015, it came up with an antibody cocktail that roughly doubled survival rates for treated patients.

Sanofi

Approach: Vaccine
Stage: Preclinical

Sanofi, which has successfully developed vaccines for yellow fever and diphtheria, is working with BARDA on an answer to the coronavirus. Sanofi’s approach involves taking some of the coronavirus’s DNA and mixing it with genetic material from a harmless virus, creating a chimera that can prime the immune system without making patients sick. Sanofi expects to have a vaccine candidate to test in the lab within six months and could be ready to test a vaccine in people within a year to 18 months. Approval would likely be at least three years away, the company said. Sanofi previously put its technology to work against SARS, a close relative of the novel virus.

Vir Biotechnology

Approach: Treatment
Stage: Preclinical

Vir Biotechnology, a company focused on infectious disease, has isolated antibodies from people who survived SARS, a viral relative of the novel coronavirus, and is working to determine whether they might treat the infection. Teaming up with Chinese pharma contractor WuXi Biologics, the San Francisco-based Vir is in the early stages of development and hasn’t specified when it expects to have products ready for human testing. Vir’s CEO, Biogen veteran George Scangos, is also coordinating the trade group BIO’s response to the coronavirus outbreak.

  • Not sure who would trust a vaccine developed practically overnight by the companies that are the biggest problem in this country. I would trust Mother Nature over big pharma ANY day of the week. And I have. Im the perfect example that there ARE other ways to live besides dependent on big pharma. of all the remedies that doctors and pharmaceutical companies say don’t work – but they actually DO work. Nature has been around way longer than these shady money hungry pharma executuves. And nature is what provided the materials for the early meds. For every drug out there- there is a more natural less dangerous remedies that would work without the side effects. I’ve lived without ANY interaction with pharma for the last 30 years and I’ve never missed one day in my whole career for sickness. So obviously something is working. And I assure you all-it has nothin to do with anything big pharma produced. Stay away from pharmaceuticals. Herbal remedies work. Whoever put us here gave us everything we need to live a healthy prosperous life. And it didn’t involve the development of drugs in a lab.

  • Willing to be injected with virus and to be tested with the vaccine to safe the world from the deadly virus ….
    And get paid fully

  • Keeping fingers crossed, with a few prayers, that one of these development firms will come up with an effective vaccine to battle this latest coronavirus!

    • Antigens(coronavirus) are proteins that are found on the surface of the pathogen. Antigens are unique to that pathogen. The whooping cough bacterium, for example, will have different antigens on its surface from the TB bacterium. When an antigen enters the body, the immune system produces antibodies against it.

  • I’m interested in getting the in injection of the Coronavirus, and staying away from every one! I just Want to know how long will I be in isolation for? Where will I be? How much do I get paid for it?

    • Knowing that companies are working on this modern ‘plague’ is very reassuring to my family. ddtjon of Ohio/USA

  • I’m interested in getting the in injection of the Coronavirus, and staying away from every one! I just have a few questions how long will I be in isolation for? Where will I be? How much do I get paid for it?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy